XML 59 R62.htm IDEA: XBRL DOCUMENT v2.4.1.9
BUSINESS COMBINATIONS - Consideration Transferred (Details) (USD $)
In Millions, except Share data, unless otherwise specified
0 Months Ended
Aug. 05, 2013
Dec. 11, 2012
Dec. 31, 2014
Dec. 31, 2013
Adjusted for the following:        
Common stock, shares outstanding     334,402,964us-gaap_CommonStockSharesOutstanding 333,036,637us-gaap_CommonStockSharesOutstanding
B&L        
Business Combinations        
Enterprise value $ 8,700.0vrx_BusinessCombinationEnterpriseValue
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Adjusted for the following:        
B&L’s outstanding debt, including accrued interest (4,248.3)us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
B&L’s company expenses (6.4)vrx_BusinessCombinationCostofAcquiredEntityCashPaidforAcquireeExpenses
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Payment in B&L’s performance-based option (48.5)vrx_BusinessCombinationCostofAcquiredEntityCashConsiderationPaidforPreviouslyCancelledOptions
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Payment for B&L’s cash balance 149.0us-gaap_CashAcquiredFromAcquisition
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Additional cash payment 75.0vrx_BusinessAcquisitionCostOfAcquiredEntityAdditionalCashPaid
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Other (3.2)us-gaap_BusinessCombinationConsiderationTransferredOther1
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Equity purchase price 4,617.6vrx_BusinessCombinationEquityPurchasePrice
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Less: Cash consideration paid for B&L’s unvested stock options (4.3)us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Total fair value of consideration transferred 4,613.3us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= vrx_BLMember
     
Medicis        
Adjusted for the following:        
Common stock, shares outstanding   57,100,000us-gaap_CommonStockSharesOutstanding
/ us-gaap_BusinessAcquisitionAxis
= vrx_MedicisPharmaceuticalCorporationMember
   
Per Share Consideration (in dollars per share)   $ 44.00us-gaap_BusinessAcquisitionSharePrice
/ us-gaap_BusinessAcquisitionAxis
= vrx_MedicisPharmaceuticalCorporationMember
   
Per Share Consideration   2,513.9us-gaap_CommonStockValueOutstanding
/ us-gaap_BusinessAcquisitionAxis
= vrx_MedicisPharmaceuticalCorporationMember
   
Number of stock options of Medicis cancelled and exchanged for cash (in shares)   3,200,000vrx_BusinessAcquisitionCostOfAcquiredEntityOptionsCancelledAndExchangedForCash
/ us-gaap_BusinessAcquisitionAxis
= vrx_MedicisPharmaceuticalCorporationMember
   
Number of stock options of Medicis cancelled and exchanged for cash   33.1vrx_BusinessAcquisitionCostOfAcquiredEntityOptionsCancelledAndExchangedForCashTotalFairValue
/ us-gaap_BusinessAcquisitionAxis
= vrx_MedicisPharmaceuticalCorporationMember
   
Number of outstanding restricted shares cancelled and exchanged for cash (in shares)   2,000,000vrx_BusinessAcquisitionCostOfAcquiredEntityRestrictedSharesCancelledAndExchangedForCash
/ us-gaap_BusinessAcquisitionAxis
= vrx_MedicisPharmaceuticalCorporationMember
   
Number of outstanding restricted shares cancelled and exchanged for cash   31.9vrx_BusinessAcquisitionCostOfAcquiredEntityRestrictedSharesCancelledAndExchangedForCashTotalFairValue
/ us-gaap_BusinessAcquisitionAxis
= vrx_MedicisPharmaceuticalCorporationMember
   
Total fair value of consideration transferred   $ 2,578.9us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= vrx_MedicisPharmaceuticalCorporationMember